ReviewDrugs & aging2005
Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines.
Review in Drugs & aging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 58 citations in OpenAlex.
- Allergy in the Elderly: A Broad Clinical Spectrum Beyond Atopy.Medicina (Kaunas, Lithuania) · 2026Article
- Identifying and Resolving Drug-Related Problems in Geriatric Patients.Hospital pharmacy · 2026Review
- Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies.International journal of molecular sciences · 2026Review
- Real-World Safety of Cyproheptadine-Based Appetite Stimulants: An Electronic Health Record-Based Retrospective Cohort Study in Adult Patients.Journal of clinical medicine · 2025Article
- Geriatric Emergency Medication Safety Recommendations (GEMS-Rx): Modified Delphi Development of a High-Risk Prescription List for Older Emergency Department Patients.Annals of emergency medicine · 2024Article
- Chronic Urticaria in Older Adults: Treatment Considerations.Drugs & aging · 2023Review
- The Usage of Histamine Type 1 Receptor Antagonist and Risk of Dementia in the Elderly: A Nationwide Cohort Study.Frontiers in aging neuroscience · 2022Article
- Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).Turkish archives of otorhinolaryngology · 2021Article
- Pharmacological Management of Allergic Rhinitis in the Elderly.Drugs & aging · 2017Review
- Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.Journal of the American Geriatrics Society · 2015Article
- Racial differences in anticholinergic use among community-dwelling elders.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2015Article
- Management of chronic spontaneous urticaria in the elderly.Drugs & aging · 2015Article
- Allergic diseases in the elderly.Clinical and translational allergy · 2011Article
- Rhinitis in the geriatric population.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2010Article
- Complexities of diagnosis and treatment of allergic respiratory disease in the elderly.Drugs & aging · 2009Review
- H1 antihistamines: current status and future directions.The World Allergy Organization journal · 2008Article
- Rhinitis in the elderly.Current allergy and asthma reports · 2006Review
- Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine.Therapeutics and clinical risk management · 2005Article
- Awareness of Family Physicians Towards Antihistamines.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of elderly persons in our society experience allergic rhinoconjunctivitis. Different agents are used in the pharmacological treatment of allergic rhinitis, with histamine H1 receptor antagonists (antihistamines) being the most frequently prescribed class. However, drug therapy of aged persons differs to a degree from that in other age groups primarily because of quantitative pharmacotherapeutic problems. The main problems are co-morbidities and polymedication, which may lead to drug-drug interactions. H1 receptor antagonists block the action of histamine at specific receptors and are available for both topical and systemic administration. First-generation H1 receptor antagonists are lipophilic and therefore may cross the blood-brain barrier; they also lack specificity for the H1 receptor. Second-generation H1 receptor antagonists have reduced capacity to cross the blood-brain barrier and greater specificity for the H1 receptor. Use of first-generation H1 receptor antagonists in the elderly should be considered carefully because of the large number of adverse effects and potential for interactions with these agents. Second-generation H1 receptor antagonists such as desloratadine, levocetirizine and ebastine provide good selective H1 receptor blockade without anticholinergic or alpha-adrenoceptor antagonist activity. Furthermore, they inhibit proinflammatory cytokines and are safe. Second-generation H1 receptor antagonists also offer therapeutic possibilities in patients with severe liver and/or renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.